Author(s):
Bhavika D. Satone, Atul A. Deshmukh, Vaishali R. Undale
Email(s):
prof.adeshmukh@gmail.com
DOI:
10.5958/0974-360X.2020.00372.8 
Address:
Bhavika D. Satone, Atul A. Deshmukh, Vaishali R. Undale
Department of Pharmacology, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Sant Tukaram Nagar, Pimpri, Pune- 411018. (M.S). India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 5,
Year - 2020
ABSTRACT:
Hypertension is the most common cardiovascular disease and is a major public health issue in developed as well as developing countries. In hypertension systolic blood pressure (SBP) rises above of 140 mmHg while diastolic blood pressure (DBP) is above of 90 mmHg. Hypertension is one of the leading cause of global burden of disease. It is one of the major cause of cardiovascular mortality, which is estimated to be 1.5 million deaths per year in India. The currently available antihypertensive drugs are not so efficient. Many ayurvedic herbs have shown antihypertensive activity. Brassica oleracea and Apium graveolens are two drugs that act on different pathophysiological mechanisms of hypertension. Hence the aim of this study was to evaluate the synergistic potential of the combination in hypertension. Antihypertension activity of combination with doses (100, 200, 400 mg/kg) was carried out with two i.e. 2K1C model and fructose induced hypertension. Biochemical estimations of Triglycerides, LDL, HDL, and Creatinine were carried out along with cardiac parameters like SBP, DBP, And Mean Blood Pressure. The results indicated dose dependent antihypertensive action of combination of drug. The antihypertensive action of combinations was found to be significantly greater than that of individual drugs thereby justifying the synergistic effect of the two drugs.
Cite this article:
Bhavika D. Satone, Atul A. Deshmukh, Vaishali R. Undale. Preclinical Evaluation of Antihypertensive Activity of Combination of Herbs Extract in Wistar Rats. Research J. Pharm. and Tech 2020; 13(5):2069-2075. doi: 10.5958/0974-360X.2020.00372.8
Cite(Electronic):
Bhavika D. Satone, Atul A. Deshmukh, Vaishali R. Undale. Preclinical Evaluation of Antihypertensive Activity of Combination of Herbs Extract in Wistar Rats. Research J. Pharm. and Tech 2020; 13(5):2069-2075. doi: 10.5958/0974-360X.2020.00372.8 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-5-2
REFERENCES:
1. Dr. Kandelwal KR. Practical Pharmacognosy. 11th ed. Nirali Prakashan, Pune. June, 2004; 149-56.
2. Ghelani HS, Patel BM, Gokani RH, Rachchh MA. Evaluation of polyherbal formulation (SJT-HT-03) for antihypertensive activity in albino rats. Ayu. 2014 Oct; 35(4):452.
3. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. Journal of Experimental Medicine. 1934 Mar 1; 59(3):347-79.
4. Hwang IS, Ho HE, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987 Nov; 10(5):512-6.
5. Tobey TA, Mondon CE, Zavaroni I, Reaven GM. Mechanism of insulin resistance in fructose-fed rats. Metabolism. 1982 Jun 1; 31(6):608-12.
6. Dai S, McNeill JH. Fructose-induced hypertension in rats is concentration-and duration-dependent. Journal of Pharmacological and Toxicological Methods. 1995 Apr 1; 33(2):101-7.
7. H. Gerhard Vogel. Drug discovery and evaluation. Springer Publication 2nd edition. March 2002 (176).
8. Vogel HG, Vogel WH, editors. Drug discovery and evaluation: pharmacological assays. Springer Science and Business Media; 2013 Apr 17.
9. Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Canadian Journal of Physiology and Pharmacology. 2003 Jun 1; 81(6):533-41.
10. Tran LT, Yuen VG, McNeill JH. The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Molecular and Cellular Biochemistry. 2009 Dec 1; 332(1-2):145-59.
11. Dai S, McNeill JH. Fructose-induced hypertension in rats is concentration-and duration-dependent. Journal of Pharmacological and Toxicological Methods. 1995 Apr 1; 33(2):101-7.
12. Sigmon DH, Beierwaltes WH. Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension. 1993 Aug; 22(2):237-42.
13. Hsueh WC, Mitchell BD, Schneider JL, Wagner MJ, Bell CJ, Nanthakumar E, Shuldiner AR. QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish. Circulation. 2000 Jun 20; 101(24):2810-6.
14. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of Internal Medicine. 2003 Nov 4; 139(9):761-76.
15. Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X. Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. Hypertension. 1999 Jun; 33(6):1324-31.
16. Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF. Genome scans for blood pressure and hypertension: The national heart, lung, and blood institute family heart study. Hypertension. 2002 Jul 1; 40(1):1-6.
17. Sontia B, Mooney J, Gaudet L, Touyz RM. Pseudohyperaldosteronism, liquorice, and hypertension. The Journal of Clinical Hypertension. 2008 Feb; 10(2):153-7.
18. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Archives of Internal Medicine. 1987 Jul 1; 147(7):1289-93.
19. Borkowski KR, Quinn P. Adrenaline and the development of spontaneous hypertension in rats. Journal of Autonomic Pharmacology. 1985 Jun; 5(2):89-100.
20. Zachary I, Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell. 1992 Dec 11; 71(6):891-4